243 related articles for article (PubMed ID: 12579318)
1. Requirement of soluble factors produced by bone marrow stromal cells on the growth of novel established human myeloma cell line.
Aikawa S; Hatta Y; Tanaka M; Kaneita Y; Yasukawa K; Sawada U; Horie T; Tsuboi I; Aizawa S
Int J Oncol; 2003 Mar; 22(3):631-7. PubMed ID: 12579318
[TBL] [Abstract][Full Text] [Related]
2. Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6.
Dezorella N; Pevsner-Fischer M; Deutsch V; Kay S; Baron S; Stern R; Tavor S; Nagler A; Naparstek E; Zipori D; Katz BZ
Exp Cell Res; 2009 Jul; 315(11):1904-13. PubMed ID: 19328780
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma.
Klein B; Zhang XG; Jourdan M; Boiron JM; Portier M; Lu ZY; Wijdenes J; Brochier J; Bataille R
Eur Cytokine Netw; 1990; 1(4):193-201. PubMed ID: 2104241
[TBL] [Abstract][Full Text] [Related]
4. Homing mechanisms in the biology of multiple myeloma.
Van Camp B; Van Riet I
Verh K Acad Geneeskd Belg; 1998; 60(3):163-94. PubMed ID: 9803879
[TBL] [Abstract][Full Text] [Related]
5. Establishment and characterization of a human stroma-dependent myeloma cell line (MM5.1) and its stroma-independent variant (MM5.2).
Van Riet I; De Greef C; Aharchi F; Woischwill C; De Waele M; Bakkus M; Lacor P; Schots R; Van Camp B
Leukemia; 1997 Feb; 11(2):284-93. PubMed ID: 9009094
[TBL] [Abstract][Full Text] [Related]
6. Effects of all-trans retinoic acid and antireceptor antibodies on growth and programmed cell death of human myeloma cells.
Taetle R; Dos Santos B; Akamatsu K; Koishihara Y; Ohsugi Y
Clin Cancer Res; 1996 Feb; 2(2):253-9. PubMed ID: 9816167
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.
Nefedova Y; Landowski TH; Dalton WS
Leukemia; 2003 Jun; 17(6):1175-82. PubMed ID: 12764386
[TBL] [Abstract][Full Text] [Related]
8. A thymic stromal cell line supports in vitro development of surface IgM+ B cells and produces a novel growth factor affecting B and T lineage cells.
Friend SL; Hosier S; Nelson A; Foxworthe D; Williams DE; Farr A
Exp Hematol; 1994 Mar; 22(3):321-8. PubMed ID: 8112430
[TBL] [Abstract][Full Text] [Related]
9. Establishment of a human myeloma cell line with growth-promoting activity for bone marrow-derived fibroblastoid colony-forming cells.
Takahira H; Kozuru M; Hirata J; Obama K; Uike N; Iguchi H; Miyamura T; Yamashita S; Kono A; Umemura T
Exp Hematol; 1994 Mar; 22(3):261-6. PubMed ID: 8112425
[TBL] [Abstract][Full Text] [Related]
10. Effect of cytokines and growth factors on the macrophage colony-stimulating factor secretion by human bone marrow stromal cells.
Besse A; Trimoreau F; Praloran V; Denizot Y
Cytokine; 2000 May; 12(5):522-5. PubMed ID: 10857771
[TBL] [Abstract][Full Text] [Related]
11. Identification of an IL-7-associated pre-pro-B cell growth-stimulating factor (PPBSF). I. Production of the non-IL-7 component by bone marrow stromal cells from IL-7 gene-deleted mice.
McKenna SD; Chen F; Lai L; Goldschneider I
J Immunol; 1998 Mar; 160(5):2272-9. PubMed ID: 9498767
[TBL] [Abstract][Full Text] [Related]
12. Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6.
Billadeau D; Liu P; Jelinek D; Shah N; LeBien TW; Van Ness B
Cancer Res; 1997 Jun; 57(11):2268-75. PubMed ID: 9187131
[TBL] [Abstract][Full Text] [Related]
13. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells.
Pedranzini L; Dechow T; Berishaj M; Comenzo R; Zhou P; Azare J; Bornmann W; Bromberg J
Cancer Res; 2006 Oct; 66(19):9714-21. PubMed ID: 17018630
[TBL] [Abstract][Full Text] [Related]
14. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor is a survival and proliferation factor for human myeloma cells.
Jourdan M; Tarte K; Legouffe E; Brochier J; Rossi JF; Klein B
Eur Cytokine Netw; 1999 Mar; 10(1):65-70. PubMed ID: 10210775
[TBL] [Abstract][Full Text] [Related]
16. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
Yasui H; Hideshima T; Raje N; Roccaro AM; Shiraishi N; Kumar S; Hamasaki M; Ishitsuka K; Tai YT; Podar K; Catley L; Mitsiades CS; Richardson PG; Albert R; Brinkmann V; Chauhan D; Anderson KC
Cancer Res; 2005 Aug; 65(16):7478-84. PubMed ID: 16103102
[TBL] [Abstract][Full Text] [Related]
17. The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone.
Grigorieva I; Thomas X; Epstein J
Exp Hematol; 1998 Jul; 26(7):597-603. PubMed ID: 9657134
[TBL] [Abstract][Full Text] [Related]
18. Pituitary adenylate cyclase-activating polypeptide is a potent inhibitor of the growth of light chain-secreting human multiple myeloma cells.
Li M; Cortez S; Nakamachi T; Batuman V; Arimura A
Cancer Res; 2006 Sep; 66(17):8796-803. PubMed ID: 16951196
[TBL] [Abstract][Full Text] [Related]
19. Interactions between leukemia cells and bone marrow stromal cells: stroma-supported growth vs. serum dependence and the roles of TGF-beta and M-CSF.
Peled A; Lee BC; Sternberg D; Toledo J; Aracil M; Zipori D
Exp Hematol; 1996 May; 24(6):728-37. PubMed ID: 8635529
[TBL] [Abstract][Full Text] [Related]
20. Restorative effect of IL-3 on adherence of cloned hemopoietic progenitor cell to stromal cell.
Minguell JJ; Hardy CL
Exp Hematol; 1993 Jan; 21(1):55-60. PubMed ID: 8417960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
